VCEL Vericel Corp Insider Trading

Vericel CLO Sean Flynn sells 15,000 shares ($603.2K) on scheduled 10b5-1 plan; retains 1,647 shares plus 70,000 stock options.

Sean C. Flynn, Chief Legal Officer of Vericel Corp, sold 15,000 shares at $40.21 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-02. Post-sale, he retains 1,647 non-derivative shares and 70,000 stock options, so his overall position remains intact. The sale is scheduled, not discretionary, limiting inference about executive sentiment. Vericel shows mixed fundamentals: strong annual revenue growth of +16.4% but recent quarterly net income of $-6.3M and an elevated P/E of 96.36, suggesting the market is pricing in future profitability improvements. Flynn's prior sales at VCEL show mixed timing outcomes (90-day returns ranging from -19.3% to +14.3%), with no clear pattern of prescience; his cross-ticker track record average of -3.0% over 90 days post-sale is similarly uninformative on this specific stock.

CLO Flynn sells 21,421 shares at blended $35.18; reduces holdings to 1,262 shares (-94.4%)

Sean C. Flynn, Chief Legal Officer of Vericel Corp, executed 2 separate sales on 2026-03-02 totaling 21,421 shares for $753,529.75 (blended average price $35.18), reducing his post-transaction holdings to 1,262 shares from a pre-transaction position of 22,683 shares. This represents a -94.4% reduction in his stake. At the current price of $34.96, the stock is -32.2% from its 52-week high of $51.53, and has declined -5.4% in the past 30 days. Flynn's prior 4 sales at VCEL have shown a mixed timing record: 3 were poorly timed (90d returns of +1.6%, +6.7%, +2.9%) while 1 was well-timed (-19.3% after the 2024-07-16 sale). Across his broader cross-ticker track record, 4 prior sells averaged a 90-day return of -2.0% with a 25.00% well-timed rate, but his VCEL-specific history shows 1 of 4 prior sales were well-timed at the 90-day mark. The magnitude of this near-total liquidation—removing 94.4% of holdings in a single filing—stands out relative to his prior transaction sizes at this ticker and warrants attention to whether operational or personal circumstances are driving this reshuffling.

Vericel CEO Colangelo sold 28,125 shares (9.7% of holdings) over 2 days for $1.2M; stock now 31.3% below 52-week high amid net income losses.

Dominick Colangelo, President and CEO, executed 2 separate sales totaling 28,125 shares for $1,178,155.89 at blended average price $41.89 on 2025-05-14 and 2025-05-15. This represents a 9.7% reduction in his holdings. The sales occurred as the stock trades 31.3% below its 52-week high of $61.80 and the company reported a net income loss of $11,246,000.00 in the latest quarter despite 20.1% annual revenue growth. His prior trades at VCEL show a 0 of 1 well-timed rate at the 90-day mark, with his most recent measurable sale on 2024-11-14 returning +3.9% over 90 days—indicating the stock rose after his sale. Current context reveals elevated operational losses and depressed valuation, but his recent same-ticker sales history at VCEL does not demonstrate well-timed exits at this ticker.

VCEL CEO Colangelo sells 49,700 shares for $2,062,550.00 in two transactions; stock down -30.7% in 90 days.

Dominick Colangelo, President and CEO of Vericel Corp, executed 2 separate sales totaling 49,700 shares for $2,062,550.00 on April 9–10, 2025, at prices of $41.11 and $41.89, representing a -16.0% reduction in his post-transaction holdings to 260,354 shares. The timing follows a sharp 90-day decline of -30.7% from the 52-week high of $61.80, with VCEL trading at $41.25 (current), -33.2% from its annual peak. His prior trades at VCEL show poor 90-day timing: 0 of 3 measurable prior sales at this ticker were well-timed (stock rose after, not fell), and his cross-ticker track record shows an avg 90d return of +9.6% after sells, indicating his sells typically preceded gains rather than declines. The stock's steep recent decline and elevated P/E of 121.32 against negative net income of $-901,000.00 in the latest quarter warrant investor attention to underlying operational health relative to valuation.

CEO Dominick Colangelo sold 53,183 shares (~17% of holdings) for $2.4M at blended avg $46.04 over 2025-03-12/13

Colangelo executed 2 separate sales totaling 53,183 shares for $2,448,810.97 on March 12–13, reducing his stake from 313,180 to 259,997 shares. The blended average price of $46.04 sits well above the current price of $45.38, and significantly above the 52-week low of $40.05, suggesting the CEO sold into strength. His prior 5 trades at VCEL showed mixed results—3 of 5 delivered positive 90-day returns (ranging +3.5% to +42.7%), but the timing pattern is neutral: 0 of 5 prior same-ticker sells were well-timed at the 90-day mark. The company reports a -26.6% drawdown from its 52-week high and faces fundamental headwinds including a loss position (net income $-901.0K) despite +20.1% annual revenue growth. The sale merits monitoring given the stock's recent -19% and -21% declines over 30 and 90 days, though the lack of a scheduled 10b5-1 plan FLAG and the absence of coordinated insider activity suggest this is discretionary rather than pre-arranged.

CMO Jonathan Mark sold 10,000 VCEL shares at $58.72 on 2024-12-02; holds 58,371 shares post-sale.

Jonathan Mark, Chief Medical Officer of Vericel Corp, sold 10,000 shares (10.0K shares) for $587,200.00 on 2024-12-02 at $58.72, reducing his holdings by 14.6% to 58,371 shares. The sale occurred near the 52-week high of $59.11 (-1.5% from peak), following a strong 30-day appreciation of +32.4%. Vericel remains unprofitable on a full-year basis (net income was negative), though the company showed robust annual revenue growth of +20.2% and generated $57,905,000.00 in latest-quarter revenue. The timing of this reduction in an executive's stake while the stock trades near yearly highs, coupled with the company's ongoing net losses despite revenue expansion, presents a datapoint worth monitoring in the context of the company's path to profitability.

VCEL CEO Colangelo sells 35,000 shares ($1.9M) in 2 transactions at $55.57 and $53.93; stock now $52.48.

Dominick Colangelo, President and CEO, executed 2 separate sales totaling 35,000 shares for $1,916,250.00 on November 13–14, 2024, at blended average price of $54.75—near the 52-week high of $56.78. Post-transaction, he retains 220,937 shares (a 13.7% reduction). The timing is notable: the stock has advanced +27.2% over the prior 30 days and +13.4% over 90 days, yet his prior trades at VCEL show only 1 of 5 measurable same-ticker outcomes well-timed at the 90-day horizon (a 0% well-timed rate). The company carries significant headwinds: annualized P/E of 749.71, net income of $-901,000.00 over the latest quarter, and full-year unprofitability, despite +20.2% annual revenue growth. The sales occurred at elevated valuation levels following a strong recent rally, in a company with deteriorating profitability metrics.

VCEL CEO Colangelo sold 35,000 shares for $1,430,100 across 2 days; stock down 22.2% from 52-week high, company unprofitable.

Dominick Colangelo, President and CEO of Vericel Corp, conducted 2 separate sales totaling 35,000 shares ($1,430,100.00) on 2024-10-16 and 2024-10-17 at blended average price $40.86, reducing his holdings by -13.7%. The transactions occurred as VCEL traded at $41.66, down 22.2% from its 52-week high of $53.56 and down 10.1% over the prior 30 days. Colangelo's prior 5 trades at VCEL show a pattern of recent selling activity (4 of the last 5 trades were sells on consecutive days in August and September), with the most measurable 90-day outcome showing a -19.7% return from the 2024-07-18 sale. The company's most recent quarter reported revenue of $52,662,000.00 but net income of $-4,682,000.00, with the company unprofitable over its full fiscal year despite posting annual revenue growth of +20.2%. His cross-ticker track record shows an average 90-day return of +4.6% on prior sells across all tickers, with a 43.75% well-timed rate, though same-ticker timing at VCEL has been mixed.

CEO Dominick Colangelo sold 35,000 VCEL shares (13.7% of holdings) in 2 tranches for $1.5M; stock unprofitable with P/E of 2293.50

Dominick Colangelo, President and CEO of Vericel Corp, executed 2 separate sales totaling 35,000 shares for $1,527,225.00 at blended average price $43.64 on September 11–12, 2024, reducing his holdings from 255,937 to 220,937 shares. The company reported net income of $-4,682,000.00 in its latest quarter and remains unprofitable on a full-year basis, while the stock trades at an extremely elevated P/E of 2293.50, reflecting minimal earnings cushion. At the same-ticker level, Colangelo's recent sells show a 0 of 1 well-timed rate at the 90-day mark, with his prior June 2024 sale returning only +1.4% over 90 days; his more recent July and August sales have recorded negative 30-day returns of −10.0% to −10.2%, though longer-term outcomes remain unmeasurable. The current stock price of $45.87 is 14.4% below its 52-week high of $53.56, creating context for evaluating this CEO-level sale against the company's fundamental weakness and the insider's mixed prior timing at this ticker.

CEO Dominick Colangelo sold 35,000 VCEL shares for $1,599,675.00 in two transactions; stock down 12.5% from 52-week high.

Dominick Colangelo, President and CEO of Vericel Corp, executed two separate sales totaling 35,000 shares for $1,599,675.00 on August 14–15, 2024, reducing his holdings from 255,937 to 220,937 shares (a 13.7% reduction of pre-transaction holdings). The blended average sale price of $45.70 is 1.2% below the current price of $46.28 but reflects execution during recent weakness: the stock is currently 12.5% below its 52-week high of $52.90 and has fallen 10.5% over the prior 30 days. At the company level, Vericel remains unprofitable (net income of $-4.7M on quarterly revenue of $52.7M) despite strong annual revenue growth of 20.2%; the valuation multiple (P/E of 2314.00) reflects the negative earnings. Colangelo's prior trade history at VCEL shows mixed timing outcomes: 1 of 1 measurable 90-day outcomes was well-timed (the May 2024 sale preceded a 5.3% decline), but two of the most recent four sales (July and June 2024) returned positive 30-day results, suggesting the recent selling window has not yet validated as a decline. This filing warrants attention given the CEO's continued discretionary selling into a stock down sharply from its recent highs, paired with the company's ongoing unprofitability.